Cognito Therapeutics is a leader in non-invasive neuromodulation aimed at treating neurodegenerative diseases and enhancing cognitive performance. The company has conducted multiple clinical studies showing promise in slowing or stopping cognitive decline and brain volume loss in Alzheimer's disease, with FDA Breakthrough Device Designation. Founded on groundbreaking optogenetics research by MIT professors, Cognito is poised to begin pivotal trials in 2022.
Cognito Therapeutics is a venture-backed company focused on translating scientific findings into therapeutic approaches for brain health, particularly in Alzheimer's disease. They are currently enrolling in a pivotal study, HOPE, and anticipate releasing topline data in summer 2026. They are seeking a motivated Manufacturing Engineer to support manufacturing processes and improve product quality.
Cognito Therapeutics is a leader in non-invasive neuromodulation aimed at treating neurodegenerative diseases and enhancing cognitive performance. The company has conducted multiple clinical studies showing promise in slowing or stopping cognitive decline and brain volume loss in Alzheimer's disease, with FDA Breakthrough Device Designation. Founded on groundbreaking optogenetics research by MIT professors, Cognito is poised to begin pivotal trials in 2022.
General Matter